Targeting the Intracellular WT1 Oncogene Product with a Therapeutic Human Antibody-Reference-Cited by-同舟云学术

Targeting the Intracellular WT1 Oncogene Product with a Therapeutic Human Antibody

Published:2013-03-13 Issue:176 Volume:5 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Dao Tao¹,Yan Su²,Veomett Nicholas¹³,Pankov Dmitry¹,Zhou Liang²,Korontsvit Tatyana¹,Scott Andrew¹,Whitten Joseph¹,Maslak Peter¹,Casey Emily¹,Tan Taochao²,Liu Hong²,Zakhaleva Victoria¹,Curcio Michael¹,Doubrovina Ekaterina¹,O’Reilly Richard J.¹³,Liu Cheng²,Scheinberg David A.¹³

Affiliation:

1. Molecular Pharmacology and Chemistry Program, Immunology Program, Departments of Medicine, Pediatrics, Pathology, and Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

2. Eureka Therapeutics, Emeryville, CA 94608, USA.

3. Weill Cornell Medical College, New York, NY 10021, USA.

Abstract

A therapeutic monoclonal antibody specific for the intracellular oncoprotein Wilms tumor 1 treats human leukemias in mice.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference50 articles.

1. Antibody-Based Immunotherapy of Cancer

2. Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma

3. Antibody therapy of cancer